— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year
— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis
— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent
— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end
— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019
— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis
— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children
Most Popular
Stock Watch : Here’s What You Need to Know before investing in Kellogg (K)
Food companies have performed better than most other sectors during the pandemic as government restrictions forced people to cook at home. Investors, in general, find the stocks of such companies
Beyond Meat (BYND) is perched rather precariously and needs to regain its footing soon
Shares of Beyond Meat Inc. (NASDAQ: BYND) gained 20% on Friday, recovering from the beating it took following the disappointing first quarter 2022 earnings report it delivered earlier this week.
JKS Earnings: Highlights of JinkoSolar’s Q1 2022 results
Solar panel manufacturer JinkoSolar Holdings Co. (NYSE: JKS) has reported a sharp increase in first-quarter revenues, reflecting higher production and shipment of modules. Meanwhile, the company's net profit declined year-over-year. Net
